StockData
Aptevo Therapeutics Inc. logo

Aptevo Therapeutics Inc. (APVO) stock

APVONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.45−0.02 (-3.25%)

Close on Nov 18, 2026Market cap $803.68KP/E –Yield –

Aptevo Therapeutics revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Aptevo Therapeutics's revenue for the twelve months ending Dec 31, 2022 was $3.11M, down 74.7% year over year. For fiscal 2022 it was $3.11M, down 74.7% from the year before. The highest annual figure on record is $33.60M in fiscal 2015.

Annual revenue

PeriodPeriod endValueChange
FY2022Dec 31, 2022$3.11M-74.7%
FY2021Dec 31, 2021$12.29M+185.3%
FY2020Dec 31, 2020$4.31M-86.7%
FY2019Dec 31, 2019$32.42M+40.6%
FY2018Dec 31, 2018$23.07M+57.4%
FY2017Dec 31, 2017$14.66M+46.8%
FY2016Dec 31, 2016$9.99M-70.3%
FY2015Dec 31, 2015$33.60M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2022Dec 31, 2022$0-100.0%
Q3 FY2022Sep 30, 2022$0-100.0%
Q2 FY2022Jun 30, 2022$0-100.0%
Q1 FY2022Mar 31, 2022$3.11M+28.6%
Q4 FY2021Dec 31, 2021$3.67M+54.4%
Q3 FY2021Sep 30, 2021$3.10M+111.6%
Q2 FY2021Jun 30, 2021$3.11M+557.5%
Q1 FY2021Mar 31, 2021$2.42M-73.2%
Q4 FY2020Dec 31, 2020$2.37M-73.7%
Q3 FY2020Sep 30, 2020$1.46M-80.1%
Q2 FY2020Jun 30, 2020$473.00K-93.3%
Q4 FY2019Dec 31, 2019$9.03M+42.3%
Q3 FY2019Sep 30, 2019$9.01M+54.7%
Q2 FY2019Jun 30, 2019$7.36M+7.8%
Q1 FY2019Mar 31, 2019$7.02M+72.5%
Q4 FY2018Dec 31, 2018$6.35M+125.2%
Q3 FY2018Sep 30, 2018$5.82M-5.6%
Q2 FY2018Jun 30, 2018$6.83M+93.6%
Q1 FY2018Mar 31, 2018$4.07M+90.1%
Q4 FY2017Dec 31, 2017$2.82M-67.9%
Q3 FY2017Sep 30, 2017$6.17M+119.2%
Q2 FY2017Jun 30, 2017$3.53M–
Q1 FY2017Mar 31, 2017$2.14M–
Q4 FY2016Dec 31, 2016$8.77M–
Q3 FY2016Sep 30, 2016$2.82M–

More Aptevo Therapeutics figures

See a number that looks wrong?